Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Greetings from the editor 2022

(2022) Josef S Smolen   ANNALS OF THE RHEUMATIC DISEASES

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

(2022) Josef S. Smolen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

(2022) Alexandre Sepriano et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

(2022) Sytske Anne Bergstra et al.   ANNALS OF THE RHEUMATIC DISEASES

Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial

(2021) René Westhovens et al.   ANNALS OF THE RHEUMATIC DISEASES

Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial

(2021) Frances Humby et al.   LANCET

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial

(2021) Bernard Combe et al.   ANNALS OF THE RHEUMATIC DISEASES

Systematic review and meta-analysis of biosimilar for the treatment of rheumatoid arthritis informing the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis

(2021) Eiichi Tanaka et al.   Modern Rheumatology

Rituximab plus leflunomide in rheumatoid arthritis: A randomised, placebo-controlled, investigator-initiated clinical trial (AMARA study)

(2021) Frank Behrens et al.   RHEUMATOLOGY

Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial

(2021) Ho So et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases

(2021) Silje Watterdal Syversen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission

(2021) Siri Lillegraven et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

POS0624 EFFICACY AND SAFETY OF LEVILIMAB IN COMBINATION WITH METHOTREXATE IN SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS: PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL

(2021) V. Mazurov et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial

(2021) Siddharth Jain et al.   ANNALS OF THE RHEUMATIC DISEASES

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

(2021) Evgeniy Nasonov et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases

(2021) Silje Watterdal Syversen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Comparison between leflunomide and sulfasalazine based triple therapy in methotrexate refractory rheumatoid arthritis: an open-label, non-inferiority randomized controlled trial

(2021) Pooja J. Belani et al.   RHEUMATOLOGY INTERNATIONAL

Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial

(2021) Koray Tascilar et al.   Lancet Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

(2020) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial

(2020) Paul Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis

(2020) Andreas Kerschbaumer et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study

(2020) Hideto Kameda et al.   RHEUMATOLOGY

Intensive therapy alleviates subclinical synovitis on ultrasound and disease activity and reduces flare in rheumatoid arthritis patients who have achieved clinical target – a randomized controlled trial

(2020) Juan Zhao et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial

(2020) Elise van Mulligen et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate‐naïve Patients with Moderately to Severely Active Rheumatoid Arthritis (SELECT‐EARLY): A Randomized, Double‐blind, Active‐comparator, Multi‐center, Multi‐country Trial

(2020) Ronald van Vollenhoven et al.   Arthritis & Rheumatology

Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial

(2020) Elise van Mulligen et al.   ANNALS OF THE RHEUMATIC DISEASES

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

(2020) Andrea Rubbert-Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE

(2020) Zhan-Guo Li et al.   ADVANCES IN THERAPY

Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY

(2020) Vibeke Strand et al.   RHEUMATOLOGY

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial

(2020) Merete Lund Hetland et al.   BMJ-British Medical Journal

Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission on Combination Therapy: A Randomized, Double‐Blind Trial

(2020) Jeffrey R. Curtis et al.   Arthritis & Rheumatology

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity

(2020) Tom W. J. Huizinga et al.   Rheumatology and Therapy

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

(2019) Tsutomu Takeuchi et al.   ANNALS OF THE RHEUMATIC DISEASES

Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study

(2019) Elise van Mulligen et al.   ANNALS OF THE RHEUMATIC DISEASES

Reducing or maintaining the dose of subcutaneous tocilizumab in patients with rheumatoid arthritis in clinical remission: a randomized, open‐label trial

(2019) Raimon Sanmarti et al.   Arthritis & Rheumatology

Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response

(2019) Roy M Fleischmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

(2019) Mark C. Genovese et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sarilumab monotherapy or in combination with non-methotrexate disease-modifying antirheumatic drugs in active rheumatoid arthritis: A Japan phase 3 trial (HARUKA)

(2019) Hideto Kameda et al.   Modern Rheumatology

Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA

(2019) Veerle Stouten et al.   RHEUMATOLOGY

Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial

(2019) Roy Fleischmann et al.   Arthritis & Rheumatology

Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial

(2019) Yoshiya Tanaka et al.   ANNALS OF THE RHEUMATIC DISEASES

An open-label randomized controlled trial of DMARD withdrawal in RA patients achieving therapeutic response with certolizumab pegol combined with DMARDs

(2019) Janet Pope et al.   RHEUMATOLOGY

Rheumatoid arthritis

(2018) Josef S. Smolen et al.   Nature Reviews Disease Primers

2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations

(2014) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM